Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 25, 2019 in Leukemia | 0 comments

In a nutshell

This study looked at the risk of kidney damage in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) therapy. Researchers found that imatinib (Gleevec) was linked with greater damage to the kidney compared to nilotinib (Tasigna) or dasatinib (Sprycel) in these patients. 

Some background

TKI therapy is a treatment for chronic myeloid leukemia. Imatinib, nilotinib, and dasatinib are TKI drugs. They work by targeting certain proteins on cancer cells. This may also lead to some damage to normal healthy cells. TKI drugs are removed from the body by the kidney. It is important to research the effects of these drugs on the kidney.

Methods & findings

595 patients with CML treated with TKIs were included in this study.  Data on patients kidney function and treatments were studied. 

In first-line treatment after 3 years, survival rates without kidney side effects were lower in the imatinib (55%) group than the nilotinib group (77%). Other factors linked with low survival rates without kidney problems included male sex and older age. 

In second- and third-line treatment, there was no difference in kidney side effects survival found between nilotinib and dasatinib.

The bottom line

The study concluded that imatinib was strongly linked with kidney side effects in the treatment of CML.

The fine print

This study looked at old data. Newer research may be needed to confirm these results.

Published By :

Annals of Hematology

Date :

May 14, 2019

Original Title :

Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.

click here to get personalized updates